Prevention and treatment of diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 68, Issue SUPPL. 1, 2005, Pages

  Wittmann, István ^a   Molnár, Gergo A ^a   Degrell, Péter ^a   Wagner, Zoltán ^a   Tamaskó, Mónika ^a   Laczy, Boglárka ^a   Brasnyó, Pál ^a   Wagner, László ^a   Nagy, Judit ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Advanced glycation endproducts; Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Diabetic proteinuria; Podocyte

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE; IRBESARTAN; METFORMIN; NEPHRIN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CONFERENCE PAPER; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DESQUAMATION; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LACTIC ACIDOSIS; MATHEMATICAL COMPUTING; MICROALBUMINURIA; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; PODOCYTE; PROTEIN DEPLETION; PROTEINURIA;

ALBUMINURIA; CREATININE; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 20444407658     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.011     Document Type: Conference Paper

References (23)

1. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.-Y. Hsu Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization N. Engl. J. Med. 351 2004 1296 1305
2. N.S. Anavekar, J.J. McMurray, E.J. Velazquez, S.D. Solomon, L. Kober, and J.-L. Rouleau Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N. Engl. J. Med. 351 2004 1285 1295
3. T.H. Hostetter Chronic kidney disease predicts cardiovascular disease N. Engl. J. M. 351 2004 1344 1346
4. M. Kestilä, U. Lenkkeri, M. Männikkö, J. Lamerdin, P. McCready, and H. Putaala Positionally cloned gene for a novel glomerular protein-nephrin is mutated in congenital nephrotic syndrome Mol. Cell 1 1998 575 582
5. S. Doublier, S. Gennaro, E. Lupia, V. Routsalainen, D. Verzola, and G. Deferrari Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II Diabetes 52 2003 1023 1030
6. R.G. Langham, D.J. Kelly, A.J. Cox, N.M. Thomson, H. Holthöffer, and P. Zaoui Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition Diabetologia 45 2002 1572 1576
7. F. Bonnet, M.E. Cooper, H. Kawachi, T.J. Allen, G. Boner, and Z. Cao Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension Diabetologia 44 2001 874 877
8. K. Zandi-Nejad, A.A. Eddy, R.J. Glassock, and B.M. Brenner Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int. 66 2004 S76 S89
9. C.N. Hales Suicide of the nephron Lancet 357 2001 136 137
10. H. Sano, R. Nagai, K. Matsumoto, and S. Horiuchi Receptors for protein modified by advanced glycation endproducts (AGE)- their functional role in atherosclerosis Mech. Ageing Dev. 107 1999 333 346
11. D. de Zeeuw, G. Remuzzi, H-H. Parving, W.F. Keane, Z. Zhang, and S. Shahinfar Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
12. The Diabetes Control and Complications Trial Research Group The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N. Engl. J. Med. 329 1993 977 986
13. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
14. P. Ruggenenti, A. Fassi, A.P. Ilieva, S. Bruno, I.P. Iliev, and V. Brusegan Preventing microalbuminuria in Type 2 diabetes N. Engl. J. Med. 351 2004 1941 1951
15. P. Phillips, and J. Braddon Oral hypoglycaemics. When not to use what Aust. Fam. Physician 31 2002 637 643
16. G. Charpentier, J.P. Riveline, and M. Varroud-Vial Management of drugs affecting blood glucose in diabetic patients with renal failure Diab. Metab. 26 2000 73 85
17. D. Devineni, Z.H. Walters, H.T. Smith, J.S. Lee, P. Prasad, and J.F. McLeod Pharmacokinetics of nateglinide in renally impaired diabetic patients J. Clin. Pharmacol. 43 2003 163 170
18. V. Hatorp Clinical pharmacokinetics and pharmacodynamics of repaglinide Clin. Pharmacokinet. 41 2002 471 483
19. M.C. Chapelsky, K. Thompson-Culkin, A.K. Miller, M. Sack, R. Blum, and M.I. Freed Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency J. Clin. Pharmacol. 43 2003 252 259
20. K. Budde, H.-H. Neumayer, L. Fritsche, W. Sulowicz, T. Stompor, and D. Eckland The pharmacokinetics of pioglitazone in patients with impaired renal function Br. J. Clin. Pharmacol. 55 2003 368 374
21. American Diabetes Association: Clinical Practice Recommendations 2004, Nephropathy in diabetes, Diab. Care 27 (Suppl. 1) (2004) S79-S83.
22. National Kidney Foundation: K/DOQI, Clinical practice guidelines for nutrition in chronic renal failure, Am. J. Kidney Dis. 35 (Suppl. 2) (2000), S1-S140.
23. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016